Literature DB >> 30291467

Self-assessment reliability in multiple sclerosis: the role of socio-demographic, clinical, and quality of life aspects.

Andrea Tacchino1, Giampaolo Brichetto2, Paola Zaratin2, Mario Alberto Battaglia3, Michela Ponzio2.   

Abstract

INTRODUCTION: Several multiple sclerosis studies matching self- and physician assessment of disease course and disability show moderate and high agreement respectively. However, the role played by socio-demographic, clinical, and quality of life (QoL) factors was not much investigated. The study aims at exploring how self-/physician agreement could depend on these variables.
MATERIALS AND METHODS: Participants were asked to report own disease course and disability according to preset categories. Kappa-value and confidence interval (CI) for disease course and two-way random interclass correlation coefficient (ICC) and CI for disability were calculated to evaluate self-/physician agreement. Χ2 was applied to examine whether other factors (gender, age, education, civil status, disease duration, fatigue, quality of life) had systematic effects.
RESULTS: Data analysis on 203 participants indicated fair agreement (Kappa-value = 0.30; 95% CI 0.23-0.38) and no dependency on the categories of each variable for disease course. Satisfactory correlation was found for disability (ICC = 0.74; 95% IC 0.67-0.80), good agreement was found for almost all variable categories, and significant differences were observed for education (better agreement for higher levels), disease duration, fatigue and QoL (better agreement for worse conditions). DISCUSSION: Results seem to suggest that higher education and worse clinical and QoL conditions could engage the patient in developing more disease awareness and realistic self-perception and self-evaluation.

Entities:  

Keywords:  Disability; Disease course; Multiple sclerosis; Self-assessment

Mesh:

Year:  2018        PMID: 30291467     DOI: 10.1007/s10072-018-3589-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  6 in total

1.  Quality of life assessment in migraine and relapsing remitting multiple sclerosis: self-perceived health is similar.

Authors:  Klaudia Duka Glavor; Marina Titlić; Gorka Vuletić; Anamarija Mrđen; Marina Maras Šimunić
Journal:  Neurol Sci       Date:  2019-07-17       Impact factor: 3.307

2.  Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.

Authors:  Jessica Podda; Andrea Tacchino; Ludovico Pedullà; Margherita Monti Bragadin; Mario Alberto Battaglia; Giampaolo Brichetto
Journal:  Mult Scler       Date:  2020-10-13       Impact factor: 5.855

3.  Glucocorticoid receptor mutations and clinical sensitivity to glucocorticoid in Chinese multiple sclerosis patients.

Authors:  Tian Song; Haoxiao Chang; Li Du; Linlin Yin; Fudong Shi; Xinghu Zhang
Journal:  Neurol Sci       Date:  2020-04-10       Impact factor: 3.307

4.  The Effect of Fatigue and Pain Self- Efficacy on Health-Related Quality of Life Among Patients with Multiple Sclerosis.

Authors:  Fevronia Adamopoulou; Victoria Alikari; Sofia Zyga; Maria Tsironi; Fotini Tzavella; Natalia Giannakopoulou; Paraskevi Theofilou
Journal:  Mater Sociomed       Date:  2019-03

5.  Personal Autonomy as Quality of Life Predictor for Multiple Sclerosis Patients.

Authors:  Rodica Padureanu; Carmen Valeria Albu; Ionica Pirici; Radu Razvan Mititelu; Mihaela Simona Subtirelu; Razvan Aurelian Turcu-Stiolica; Harri Sintonen; Vlad Padureanu; Adina Turcu-Stiolica
Journal:  J Clin Med       Date:  2020-05-05       Impact factor: 4.241

6.  Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model.

Authors:  Ingrid E H Kremer; Mickael Hiligsmann; Josh Carlson; Marita Zimmermann; Peter J Jongen; Silvia M A A Evers; Svenja Petersohn; Xavier G L V Pouwels; Nick Bansback
Journal:  Med Decis Making       Date:  2020-11       Impact factor: 2.583

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.